Home › Type 1 Diabetes › NCT05317455
Regulation of Brain Glucose Metabolism in Type 1 Diabetes
RecruitingEarly phase 1
Who can join
Ages 18 to 55 · All sexes
Full eligibility criteria
Inclusion Criteria: T1DM subjects with: * a history of severe hypoglycemia and/or hypoglycemia unawareness or * a history of severe hypoglycemia with a blood glucose \<54 mg/dL, requiring the assistance of another person (with recovery after the administration of oral carbohydrate, intravenous glucose, or glucagon) or * at least 2 values \<54mg/dl during 2 weeks of CGMS testing during the week prior to study. Exclusion Criteria: * Age \< 18 years or \>55 years. * Body weight \>85 kg at screening visit * BMI \> 30 (female) and \>30 (male) kg/m2. * Untreated proliferative retinopathy * carriers of glutathione transferase Z1 (GSTZ-1) gene polymorphisms that predispose to DCA accumulation and toxicity
About the study
This is a prospective randomized placebo-controlled double-blind crossover pilot study determining the effect of dichloroacetate on brain function under clamped hypoglycemia in T1DM.
What is being tested
- Dichloroacetate (drug)
Sponsor: Yale University · Participants: 16 · Started: May 13, 2025
Contact the study team
- Alice Hahn · Phone: 4753210504
Official record on ClinicalTrials.gov — NCT05317455
Locations in the U.S.
| Connecticut | Yale-New Haven Hospital, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.